Atlas Trials

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

Clinical trial NCT04343885 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04343885
Sponsor
Peter MacCallum Cancer Centre, Australia
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Hormone Naive Prostate Cancer
Start date
2020-04-21
Primary completion
2026-03-01
Enrollment
130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.